JWJames Wilson

James Wilson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Wilson has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time From Symptom Onset to Treatment Initiation in Visceral Leishmaniasis In Brazil, 2007–2023: A National Notifiable Disease Registry-Based Study

    by Juan Sebastian Hurtado, James P. Wilson, Dawit Getachew Assefa, Makoto Saito, Philippe J. Guérin, Neal Alexander, Glaucia Cota, Prabin Dahal

    Background: Prompt diagnosis and treatment remain key to global visceral leishmaniasis (VL) control. Despite this, a long gap between symptom onset and treatment initiation has often been reported in different endemic countries.Methods: VL surveillance data were obtained from Brazil’s Sistema de Informação de Agravos de Notificação (SINAN) system (2007–2023). The primary exposure was the number of days between reported symptom onset and the treatment initiation (TTI). Cox regression was used to investigate the impact of TTI on mortality within 12 months of treatment. Findings: A total of 35,186 confirmed cases of primary VL were included. The TTI gap was best described by a log-normal distribution; based on this model, 50%, 75%, and 95% of patients received treatment within 26, 56, and 169 days, respectively. The median (interquartile range, IQR) TTI increased progressively with patients’ age: 21 days (IQR: 12-36) among <15y and 35 days (IQR: 17–73) among ≥15 years. Patients with TTI ≥120 days had a 12-months survival of 0·86 [95% confidence interval (95% CI): 0·83–0·89] compared to 0·89 [95% CI: 0·87–0·92] among those with TTI ≤14 days (P <0·001, log-rank test), and 0·91 [95% CI: 0·90–0·92] among those with TTI between 15–30 days (P=0·001, log-rank test). Age less than 5 years, the South region, and HIV co-infection were associated with increased mortality in the multivariable Cox model. Interpretation: Early presentation was associated with a higher 12-month survival. These findings provide insights into optimising patient management and disease control efforts in Brazil.

  • Open Access

    Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

    by James Patrick Wilson, Forhad Chowdhury, Shermarke Hassan, Elinor Harriss, Fabiana Alves, Ahmed Musa, Prabin Dahal, Kasia Stepniewska, Philippe J Guérin

    Background: Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty and poor nutrition. Without effective treatment, death is the norm. Prognostic models can steer clinical decision-making by identifying patients at high risk of adverse outcomes. We aimed to identify, summarise and critically appraise prognostic models predicting future clinical outcomes in patients with VL. Methods: We systematically reviewed all studies that developed, evaluated or updated prognostic models predicting future clinical outcomes in patients diagnosed with VL. Five bibliographic databases (Ovid Embase, Ovid MEDLINE, Web of Science Core Collection, SciELO and LILACS) were searched from database inception to 1 March 2023, with an update to 18 December 2025. Screening, data extraction and risk of bias assessment (Prediction Model Risk of Bias Assessment Tool) were performed independently and in duplicate. Results are presented with tables, figures and a narrative synthesis. Results: Eight studies, published between 2003 and 2021, were identified describing 12 prognostic model developments. 10 models were evaluated in settings that were either geographically or temporally distinct from those used for model development, resulting in 19 external validations. All models predicted mortality, either using hospital-based cohorts (10 models) or registry data (2 models), and were developed in either Brazilian or East African populations (9 and 3 models, respectively). Model discrimination (c-statistics) ranged from 0.56 to 0.93 when evaluated in the same patients used for model development (apparent performance, 12 models), and 0.62 to 0.92 when evaluated in new settings (19 external validations, 10 models). All model developments and evaluations were judged at high risk of bias: no studies presented calibration plots, 11 models were at high risk of overfitting due to small sample sizes, and four models presented risk scores that did not correspond to the reported regression coefficients. Conclusions: All identified models predict mortality and were developed in Brazilian or East African patient populations. No prognostic models were identified that predict treatment failure or relapse, and despite South Asia accounting for the highest global VL burden prior to 2010, no models were developed in this population. Within the context of the ongoing elimination programmes in South Asia and East Africa, these represent important evidence gaps where new model development should be prioritised. Information presented in this review can be used by clinicians and policymakers to assess the applicability of existing models to their own patient settings. However, with a high risk of bias identified for all models, caution should be exercised when interpreting model risk and performance estimates. We direct interested readers to expert guidance to support transparent reporting and reduce common sources of bias in the development and evaluation of prediction models. PROSPERO registration number: CRD42023417226.

  • Open Access

    Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies

    by Prabin Dahal, Sauman Singh-Phulgenda, James Wilson, Glaucia Cota, Koert Ritmeijer, Ahmed Musa, Fabiana Alves, Kasia Stepniewska, Philippe J Guerin

    Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises the transfusion practices adopted in VL efficacy studies using the Infectious Diseases Data Observatory VL clinical trials library. Of the 160 studies (1980–2021) indexed in the IDDO VL library, description of blood transfusion was presented in 16 (10.0%) (n=3459 patients) studies. Transfusion was initiated solely based on haemoglobin (Hb) measurement in nine studies, combining Hb measurement with an additional condition (epistaxis/poor health/clinical instability) in three studies and the criteria was not mentioned in four studies. The Hb threshold range for triggering transfusion was 3–8 g/dL. The number of patients receiving transfusion was explicitly reported in 10 studies (2421 patients enrolled, 217 underwent transfusion). The median proportion of patients who received transfusion in a study was 8.0% (Interquartile range: 4.7% to 47.2%; range: 0–100%; n=10 studies). Of the 217 patients requiring transfusion, 58 occurred before VL treatment initiation, 46 during the treatment/follow-up phase and the time was not mentioned in 113. This review describes the variation in clinical practice and is an important initial step in policy/guideline development, where both the patient's Hb concentration and clinical status must be considered.


  • Open Access

    Prognostic Models Predicting Clinical Outcomes in Patients Diagnosed with Visceral Leishmaniasis: A Systematic Review

    by James Patrick Wilson, Forhad Chowdhury, Shermarke Hassan, Eli P Harriss, Fabiana Alves, Ahmed Musa, Prabin Dahal, Kasia Stepniewska, Philippe J Guerin

    Background Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty and poor nutrition. Without treatment, death is the norm. Prognostic models can steer important management decisions by identifying patients at high-risk of adverse outcomes. We therefore aim to identify, summarise, and appraise the available prognostic models predicting clinical outcomes in VL patients. Methods We reviewed all published studies that developed, validated, or updated models predicting clinical outcomes in VL patients. Five bibliographic databases were searched from database inception to March 1st 2023 with no language restriction. Screening, data extraction, and risk of bias assessment were performed in duplicate. Findings are presented with tables, figures, and a narrative review. Results Eight studies, published 2003-21, were identified describing 12 model developments and 19 external validations. All models predicted either in-hospital mortality (n=10 models) or registry-reported mortality (n=2), and were developed in either Brazilian or East African settings (n=9 and n=3 models respectively). Model discrimination (c-statistic) ranged from 0.62-0.92 when evaluated in new data (19 external validations, 10 models). Risk of bias was high for all model developments and validations: no studies presented calibration plots, 11 models were at high risk of overfitting due to small sample sizes, and six models presented risk scores that were inconsistent with reported regression coefficients. Conclusion With a high risk of bias identified for all models, caution must be exercised when interpreting model predictions and performance measures. Prior to model development or validation, we encourage investigators to review model reporting guidelines. No prognostic models were identified predicting treatment failure or relapse. Furthermore, despite South Asia representing the highest VL burden pre-2010, no models were developed in this population. In the context of the current South Asia elimination programme, these represent important evidence gaps where new model development should be prioritised. Registration details A protocol for this systematic review has been published (1) and registered (PROSPERO ID: CRD42023417226). What is already known on this topic Visceral leishmaniasis (VL) is a neglected tropical disease associated with high mortality, and endemic to regions with constrained resources. Identification of high-risk patients is important when prioritising the allocation of limited resources, including inpatient beds, certain VL treatments, and follow-up clinic capacity. Risk stratification of VL patients can be performed using prognostic models, however, the range of models, and important model characteristics, have yet to be systematically evaluated. What this study adds Following reporting guidelines for systematic reviews of prediction model studies, we present the first comprehensive review of prognostic models that predict clinical outcomes in VL patients. We describe 12 prognostic models that all predict mortality in Brazil or East Africa. All identified models, including model validations, are assessed at high risk of bias – model predictions and performance measures should be interpreted with caution. How this study might affect research, practice or policy This review allows investigators to assess important evidence gaps in the VL prediction model landscape, and identify candidate models for validation or updating using their own patient data. Models are identified, summarised, and appraised so that policymakers and healthcare providers can assess model applicability to their own patient population. By highlighting limitations in the interpretation of model predictions and performance measures, and to address common sources of bias, we encourage investigators interested in prediction model research to review current guidelines in model reporting, including recently published tools for the calculation of sample sizes and model presentation.

  • Open Access

    Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis

    by Abdalla Munir, Prabin Dahal, Rishikesh Kumar, Sauman Singh-Phulgenda, Niyamat Ali Siddiqui, Caitlin Naylor, James Wilson, Gemma Buck, Manju Rahi, Fabiana Alves, et al.

    Introduction: Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. Despite anaemia being a common haematological manifestation of VL, the evolution of different haematological characteristics following treatment remains poorly understood. An individual participant data meta-analysis (IPD-MA) is planned to characterise the haematological dynamics in patients with VL. Methods and analysis: The Infectious Diseases Data Observatory (IDDO) VL data platform is a global repository of IPD from therapeutic studies identified through a systematic search of published literature (PROSPERO registration: CRD42021284622). The platform currently holds datasets from clinical trials standardised to a common data format. Corresponding authors and principal investigators of the studies indexed in the IDDO VL data platform meeting the eligibility criteria for inclusion were invited to be part of the collaborative IPD-MA. Mixed-effects multivariable regression models will be constructed to identify determinants of haematological parameters by taking clustering within study sites into account. Ethics and dissemination: This IPD-MA meets the criteria for waiver of ethical review as defined by the Oxford Tropical Research Ethics Committee (OxTREC) granted to IDDO, as the research consists of secondary analysis of existing anonymised data (exempt granted on 29 March 2023, OxTREC REF: IDDO). Ethics approval was granted by the ICMR-Rajendra Memorial Research Institute of Medical Sciences ethics committee (letter no.: RMRI/EC/30/2022) on 4 July 2022. The results of this analysis will be disseminated at conferences, the IDDO website and peer-reviewed publications in open-access journals. The findings of this research will be critically important for control programmes at regional and global levels, policymakers and groups developing new VL treatments. PROSPERO registration number: CRD42021284622.


  • Open Access

    Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

    by Rishikesh Kumar, Prabin Dahal, Sauman Singh-Phulgenda, Niyamat Ali Siddiqui, Abdalla Munir, Caitlin Naylor, James Wilson, Gemma Buck, Manju Rahi, Paritosh Malaviya, et al.

    Introduction Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current first-line therapies across different regions. Such heterogeneity could be a function of host, parasite and drug factors. An individual participant data meta-analysis (IPD-MA) is planned to explore the determinants of treatment outcomes. Methods and analysis The Infectious Diseases Data Observatory (IDDO) VL living systematic review (IDDO VL LSR) library is an open-access resource of all published therapeutic studies in VL since 1980. For this current review, the search includes all clinical trials published between 1 January 1980 and 2 May 2021. Studies indexed in the IDDO VL LSR library were screened for eligibility for inclusion in this IPD-MA. Corresponding authors and principal investigators of the studies meeting the eligibility criteria for inclusion were invited to be part of the collaborative IPD-MA. Authors agreeing to participate in this collaborative research were requested to share the IPD using the IDDO VL data platform. The IDDO VL data platform currently holds data sets from clinical trials standardised to a common data format and provides a unique opportunity to identify host, parasite and drug determinants of treatment outcomes. Multivariable regression models will be constructed to identify determinants of therapeutic outcomes using generalised linear mixed-effects models accounting for within-study site clustering. Ethics and dissemination This IPD-MA meets the criteria for waiver of ethical review as defined by the Oxford Tropical Research Ethics Committee (OxTREC) granted to IDDO, as the research consists of secondary analysis of existing anonymised data (Exempt granted on 29 March 2023, OxTREC REF: IDDO) Ethics approval was granted by the ICMR-Rajendra Memorial Research Institute of Medical Sciences ethics committee (Letter no: RMRI/EC/30/2022) on 04-07-2022. The results of this IPD-MA will be disseminated at conferences, IDDO website and any peer-reviewed publications. All publications will be open source. Findings of this research will be critically important for the control programmes at regional/global levels, policy makers and groups developing new VL treatments. PROSPERO registration CRD42021284622.


  • Open Access

    Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review

    by James Wilson, Forhad Chowdhury, Shermarke Hassan, Elinor K Harriss, Fabiana Alves, Prabin Dahal, Kasia Stepniewska, Philippe J Guérin

    Introduction Visceral leishmaniasis (VL) is a neglected tropical disease responsible for many thousands of preventable deaths each year. Symptomatic patients often struggle to access effective treatment, without which death is the norm. Risk prediction tools support clinical teams and policymakers in identifying high-risk patients who could benefit from more intensive management pathways. Investigators interested in using their clinical data for prognostic research should first identify currently available models that are candidates for validation and possible updating. Addressing these needs, we aim to identify, summarise and appraise the available models predicting clinical outcomes in VL patients. Methods and analysis We will include studies that have developed, validated or updated prognostic models predicting future clinical outcomes in patients diagnosed with VL. Systematic reviews and meta-analyses that include eligible studies are also considered for review. Conference abstracts and educational theses are excluded. Data extraction, appraisal and reporting will follow current methodological guidelines. Ovid Embase; Ovid MEDLINE; the Web of Science Core Collection, SciELO and LILACS are searched from database inception to 1 March 2023 using terms developed for the identification of prediction models, and with no language restriction. Screening, data extraction and risk of bias assessment will be performed in duplicate with discordance resolved by a third independent reviewer. Risk of bias will be assessed using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Tables and figures will compare and contrast key model information, including source data, participants, model development and performance measures, and risk of bias. We will consider the strengths, limitations and clinical applicability of the identified models. Ethics and dissemination Ethics approval is not required for this review. The systematic review and all accompanying data will be submitted to an open-access journal. Findings will also be disseminated through the research group’s website (www.iddo.org/research-themes/visceral-leishmaniasis) and social media channels. PROSPERO registration number CRD42023417226.


  • Open Access

    Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation.

    by P Bradley, J Wilson, R Taylor, J Nixon, J Redfern, P Whittemore, M Gaddah, K Kavuri, A Haley, P Denny, et al.


  • Open Access

    Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis

    by Claire J. Calderwood, James P. Wilson, Katherine L. Fielding, Rebecca C. Harris, Aaron S. Karat, Raoul Mansukhani, Jane Falconer, Malin Bergstrom, Sarah M. Johnson, Nicky McCreesh, et al.

    Background: Two weeks’ isolation is widely recommended for people commencing treatment for pulmonary tuberculosis (TB). The evidence that this corresponds to clearance of potentially infectious tuberculous mycobacteria in sputum is not well established. This World Health Organization–commissioned review investigated sputum sterilisation dynamics during TB treatment. Methods and findings: For the main analysis, 2 systematic literature searches of OvidSP MEDLINE, Embase, and Global Health, and EBSCO CINAHL Plus were conducted to identify studies with data on TB infectiousness (all studies to search date, 1 December 2017) and all randomised controlled trials (RCTs) for drug-susceptible TB (from 1 January 1990 to search date, 20 February 2018). Included articles reported on patients receiving effective treatment for culture-confirmed drug-susceptible pulmonary TB. The outcome of interest was sputum bacteriological conversion: the proportion of patients having converted by a defined time point or a summary measure of time to conversion, assessed by smear or culture. Any study design with 10 or more particpants was considered. Record sifting and data extraction were performed in duplicate. Random effects meta-analyses were performed. A narrative summary additionally describes the results of a systematic search for data evaluating infectiousness from humans to experimental animals (PubMed, all studies to 27 March 2018). Other evidence on duration of infectiousness—including studies reporting on cough dynamics, human tuberculin skin test conversion, or early bactericidal activity of TB treatments—was outside the scope of this review. The literature search was repeated on 22 November 2020, at the request of the editors, to identify studies published after the previous censor date. Four small studies reporting 3 different outcome measures were identified, which included no data that would alter the findings of the review; they are not included in the meta-analyses. Of 5,290 identified records, 44 were included. Twenty-seven (61%) were RCTs and 17 (39%) were cohort studies. Thirteen studies (30%) reported data from Africa, 12 (27%) from Asia, 6 (14%) from South America, 5 (11%) from North America, and 4 (9%) from Europe. Four studies reported data from multiple continents. Summary estimates suggested smear conversion in 9% of patients at 2 weeks (95% CI 3%–24%, 1 single study [N = 1]), and 82% of patients at 2 months of treatment (95% CI 78%–86%, N = 10). Among baseline smear-positive patients, solid culture conversion occurred by 2 weeks in 5% (95% CI 0%–14%, N = 2), increasing to 88% at 2 months (95% CI 84%–92%, N = 20). At equivalent time points, liquid culture conversion was achieved in 3% (95% CI 1%–16%, N = 1) and 59% (95% CI 47%–70%, N = 8). Significant heterogeneity was observed. Further interrogation of the data to explain this heterogeneity was limited by the lack of disaggregation of results, including by factors such as HIV status, baseline smear status, and the presence or absence of lung cavitation. Conclusions: This systematic review found that most patients remained culture positive at 2 weeks of TB treatment, challenging the view that individuals are not infectious after this interval. Culture positivity is, however, only 1 component of infectiousness, with reduced cough frequency and aerosol generation after TB treatment initiation likely to also be important. Studies that integrate our findings with data on cough dynamics could provide a more complete perspective on potential transmission of Mycobacterium tuberculosis by individuals on treatment. Trial registration: Systematic review registration: PROSPERO 85226.


  • Open Access

    Continuous positive airway pressure (CPAP) as a ceiling of care treatment for hypoxemic respiratory failure due to COVID-19

    by Patrick Bradley, Jennifer Nixon, James Wilson, James Redfern, Tarek Saba, Emily Nuttall, Thomas Bongers